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ABSTRACT 
In this study, out of sixteen compounds, only thirteen compounds have shown hydrogen bonding with the modeled cathepsin B protein of L 
donovani, remaining compound (C1D13416238, Posaconazole. and CID 6082033) did not show any hydrogen bonding with ligands. So, these 13 
compounds which show hydrogen bonding with modeled protein could be considered as most potent lead compounds having inhibitory activity 
at either promastigote stage or amastigote stage of Leishmania donovani. Few compounds demonstrated better docking score to either 
AutoDock4.0 or GOLD v2.l but some compound did not show any hydrogen bonding with modeled protein in either docking software tool. Thus, 
it could be concluded that generated experimental compounds could have potential as pharmacological tool against Visceral Leishmaniasis.  
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INTRODUCTION 
Leishmaniasis is a complex vector-borne disease caused by 
at least seventeen different species of Leishmania  protozoan 
parasites 1. Four types of Leishmaniasis are seen to affect the 
human i.e. Visceral Leishmaniasis (VL), Cutaneous 
Leishmaniasis (CL), Mucocutaneous Leishmaniasis (ML) and 
Post Kala-azar Dermal Leishmaniasis (PKDL). Human 
leishmaniasis is distributed worldwide, more frequent in the 
tropics and sub-tropics regions with a predominance of over 
12 million cases and an approximated incidence of 0.5 and 
1.5 million cases of VL and CL respectively. In humans, it 
manifests either as a cutaneous disease caused mainly by L. 
major, L.  tropica, and L.  mexicana, as a mucocutaneous 
disease caused mainly by L. braziliansis, or as a visceral 
disease caused mainly by L. donovani and L. chagasi. 
Phlebotomine sand flies transmits leishmanial diseases to 
their vertebrate hosts, which acquire the pathogen by 
feeding on infected hosts and transmit them by regurgitating 
the parasite at the site of a subsequent blood meal 2. While 
obtaining a blood meal, sand flies salivate   into the host’s 
skin. This saliva contains anti-clotting, anti-platelet and 
vasodilatory compounds that increase the hemorrhagic pool 
where sand flies feed 3. An estimated 0.9–1.3 million (9 to 13 
lakhs) new cases and 20 000 to 30 000 death due to 
Leishmaniasis, a dreadful parasitic disease occur annually 4. 
It has been reported that the number of persons at risk of 
contracting Leishmaniasis is approximately 350 million and 
there are 2.3 million new cases reported every year 5. The 
genus Leishmania is the causative agent of Leishmaniasis, a 
severe parasitic disease of considerable importance in terms 
of both diversity and complexity. All Leishmania species are 
having digenetic life cycle and alternate between the 
flagellated mobile promastigotes to non-flagellated and non-
motile amastigotes 6. Visceral Leishmaniasis (VL), also 
known as Kala-azar, black fever, and Dum-Dum fever, is the 
most severe form of leishmaniasis 7.  
In the present study, a homology model of the LdvCP 
(cysteine protease) was constructed to obtain an in-depth 
idea of this protein’s structural and functional 
characteristics. The construction of 3D model of the L. 
donovani cysteine protease based on available 3D structure 
of the cysteine protease from protein data bank was done by 
homology modeling. The predicted structures were refined 
by taking advantages of the CHARMM parameters and 
energy minimization studies and were evaluated using the 
DOPE (Discrete Optimized Protein Energy) score, PROCHECK 
and Verify3D to analyze the structural integrity. Analogues, 
different natural compounds from available databases and 
currently implicated antileishmanial compounds were 
docked into the active site of 3D model protein. The 
designing of novel compounds was based on pharmacophore 
mapping, and 3D-QSAR studies of different inhibitors against 
cysteine protease of Leishmania parasite. 
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MATERIALS AND METHODS 
Parasite Culture 
Promastigotes of Indian Leishmania donovani strain 
MHOM/IN/83/AG83 was obtained from culture bank of 
Rajendra Memorial Research Institute of Medical Sciences 
(RMRIMS), Patna, India. The cryo-cells were revived and 
grown in RPMI1640 medium (Sigma-Aldrich) supplemented 
with 10% Fetal Calf Serum (FCS: Sigma-Aldrich) in BOD 
incubator at 22°C. 
Genomic DNA Isolation  
Genomic DNA isolation was done by using standard procol of 
PureLinkTM Genomic DNA kit. 1ml of culture was taken and 
centrifuged in 10,000 rpm for 10 minutes at 0°C, then the 
discard the supernatant and keeps the palette. 200 µl of PBS 
was added to the palette. 20 µl Proteinase K and 20 µl RNase 
A was added to the sample. Then by brief vortexing it was 
mixed wel. Then the mixture was incubated at room 
temperature for 2 minutes. 200 µl PureLink™ Genomic 
Lysis/Binding Buffer was added to the same tube and then 
again mixed well by vortexing to obtain a homogenous 
solution. This mixture was incubated at 55°C for 10 minutes 
to promote protein digestion. 200 µl of absolute ethanol was 
added to the lysate. The solution mixed well by vortexing to 
yield a homogenous solution.  
A PureLink™ Spin Column in a Collection Tube was taken and 
prepared by  lysate (~640 µl) was added to the spin column. 
The column was centrifuge at 10,000 × g for 1 minute at 
room temperature. Then the collection tube was discarded 
and the spin column was placed into a clean PureLink™ 
Collection Tube supplied with the kit. 500 µl Wash Buffer 1 
was added to the column, centrifuged at 10,000 × g for 1 
minute at room temperature. The flow through was 
discarded and 500 µl Wash Buffer 2 prepared with ethanol 
was added to the column, centrifuged the column at 
maximum speed for 3 minutes at room temperature. Then 
collection tube was discarded. The spin column was placed 
in a sterile 1.5-ml microcentrifuge tube. 100µl of PureLink™ 
Genomic Elution Buffer was added to the column and kept 
for 5mins and then centrifuged at maximum speed for 1 
minute at room temperature. Now the column was discarded 
and purified DNA was stored at -20°C (long-term). 
 
 
RESULTS AND DISCUSSION  
DNA Isolation, Primer designing and amplification of 
cysteine protease Gene 
Leishmania promastigote strain MHOM/IN/83/AG83 were 
grown in RPMI1640 medium in supplemented with 10% 
heat inactivated Fetal Calf Serum (FCS) and subjected to DNA 
extraction using an DNA isolation kit (Qiagen). Total DNA 
was taken as electrophoresis on 1.2% agarose gel. Figure 
3.1(A) shows that total DNA has been extracted and 
concentration of the extracted DNA is quite high. DNA was 
stored at -20ºC. Cysteine protease gene was amplified from 
total DNA pool using cysteine protease specific primers 
designed against cysteine protease of L. major. The PCR 
product was analyzed by electrophoresis on 1.2% agarose 
gel and photographed. The size marker used to estimate PCR 
products is 1kbp DNA ladder (Sigma). Figure 3.1(B) shows 
the PCR product of the L. donovani cysteine protease gene. 
The gel picture shows that the size of PCR product is about 
1185bp and is similar to the L. major cysteine protease gene 
size (as reported in NCBI) and no other gene is amplified. 
Thus, these designed primers are specific for amplifying of 
cysteine protease gene from L. donovani. 
Sequencing of the PCR Product, Sequence and 
Phylogenetic Analysis 
The PCR product was then processed and purified to run 
sequencing PCR, and loaded on ABI 3130xL genetic analyzer 
for sequencing. The PCR product was sequenced twice once 
with forward primer and once with reverse primer. 
Nucleotide in each position was considered correct if two 
sequencing results (which were sequenced in opposite 
directions) confirmed each other. Translated sequence 
similarities between cysteine protease gene within same 
species and sequence dissimilarity with the human cysteine 
protease gene was predicted by using Clustal W and 
cladogram shown in Figure 1. The translated amino acid 
sequence of cysteine protease protein consisting of 211 
amino acids was analyzed to know evolutionary relationship 
with other known species. Further sequence analysis of 
cysteine protease of Ldv revealed that it has 82-100% 
sequence identity with L. infantum, L. major, L. tarentolae, T. 
cruzi and L. braziliensis amino acid sequences . A 
Phylogenetic analysis by maximum likelihood method 
exhibited that cysteine protease of Ldv clusters with other 
species 91% with Leishmania sp. (PDB ID 6EX8) and varies in 
between 82-100 % with same Leishmania species. 
   
    
Figure 1A: Electrophoresis of PCR product for Leishmania donovani cysteine protease gene from patient blood, from left to right 
=>Line 1: 2 cysteine protease gene (~1185bp), Lane 2: DNA ladder Kbp. 1B : Electrophoresis of PCR product for Leishmania 
donovani (AG83 strain)gene from culture, from left to right =>Line 1:2 DNA ladder Kbp, cysteine protease gene(1185bp). 
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Figure 2: Based on the multiple sequences alignment we retrieved the conserved regions with different species was carried out 
using clustal W server. The red color star indicates the conserved region and the identified conserved regions are representing in 
Prim.cons. sequence as shown in figure. 
 
CONCLUSION 
Leishmania cysteine proteases are potential target for 
treating visceral Leishmaniasis. In order to understand 
structural features we carried out homology modeling of 
Leishmania donovani cathepsin B and cathepsin L like 
cysteine protease. The lack of crystal structure and 
structural data for validated targets are the major problem 
that faced cysteine protease inhibitor that may represent the 
important step towards the assessment of anti-leishmanial 
chemotherapy. Developed model shows good overall 
structural quality as validated by using different validation 
tools like PROCHECK, VERIFY 3D score. In addition, model 
shows good native protein folding. The ligand active site was 
determined by sequence alignment and PAR 3D analysis tool. 
The amino acid residues Cys29, Hisl88 and Asn208 of 
cathepsin B of Leishmania donovani are active site residues, 
which were exploited to design target specific inhibitors. The 
cathepsin B model was taken for further screening of 
different chemical library for studying their cathepsin B 
inhibitory activities, different public domain chemical 
libraries were accessed for this study and many compounds 
have been generated using Chemsketch program.  
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